Objective: Cluster of differentiation (CD) 74, CD44, and macrophage migration inhibitory factor (MIF) are well known for their immunological functions; however, it has been shown that recently, CD74, CD44, and MIF have a role in tumor and tumor progression. This study was undertaken to investigate the expression of CD74, MIF, and CD44 in breast cancer cells.
Introduction
A number of molecules play a key role to play a crucial role in tumor progression. These include cluster of differentiation (CD) 74, macrophage migration inhibitory factor (MIF), and CD44. [1] These molecules have been recognized in several types of cancers and are supposed to be playing a crucial role in immunotolerance. [2] CD74 expression has been observed in several types of cancer including multiple myeloma and in various solid tumor cancers such as gastric cancer, kidney, and small-cell lung cancer. [3] [4] [5] [6] CD74, along with CD44, has been suggested to mediate MIF signaling pathway in bladder and prostate cancer cell lines. [1, 7] MIF has a critical role in tumorigenesis due to its overexpression by cancer cells; it is widely documented that MIF is overexpressed in breast cancer, prostate cancer, and colon carcinoma tumors. [8] CD44 is able to promote tumor cell invasiveness, self-renewal and sustained survival, and has the ability to prompt many types of cancer. [9, 10] Till date, CD74 coexpression with MIF or with CD44 was not fully defined in breast cancer; however, few studies have shown their expression in prostate cancer and also in lung cancer. [7, 11] Recently, Richard et al. [12] studied the involvement of MIF and its receptor CD74 in human breast cancer. However, they did not consider the relationship between CD74 and MIF and the expression of CD44. It is proposed herein that coexpression of CD74/MIF and CD44 might play a key role in progression and survival of breast tumor, in addition to the role that each molecule individually has in breast tumor. The primarily purpose of this study was to study the expression profile of CD74, MIF, and CD44 molecules on the breast cancerderived cell lines CAMA-1, 3,4-methylenedioxyamphetamine (MDA)-MB-231, and MDA-MB-435. To validate this study the expression of CD74, MIF, and CD44 on the normal breast cell line 266LDM, whole cell lysate obtained from adult normal
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Materials and Methods

Cell culture
Human mammary gland cell lines CAMA-1, MDA-MB-231, MDA-MB-435, and immortalized normal breast luminal cells (226LDM) were commercially obtained from American Type Culture Collection (ATCC, Middlesex, UK) and were cultured as described by manufacturer's instructions (ATCC), whereas HeLA cells, Jurkat cells, and Raji cell were also purchased from ATCC (Middlesex, UK) and were used as positive control.
Flow cytometry
All cell lines used in this study were subjected to analyze the cell surface or intracellular expression of CD74, MIF, and CD44 by flow cytometry (FlowJo 8.8.6) using monoclonal antibodies By2 (anti-CD74), ab55445 (anti-MIF), 156-3C11 (anti-CD44), W6/32 (anti-HLA-A, B, and C), and LN3 (anti-HLA-DR) as described previously. [13, 14] 
Western blotting
Protein expression of the desired proteins was analyzed by western immunoblotting using anti-CD74 (clone: By2), anti-MIF (clone: ab55445), and anti-CD44 (clone: 156-3C11) antibodies as described previously. [14] Immunostaining CAMA-1, MDA-MB-231, and Raji cell lines were grown individually in 8 well chambers (LabTek, Thermo Fisher Scientific) for 48 h and staining was conducted when reached at appropriate density. All staining steps were performed at 25°C, cells were fixed with paraformaldehyde (4%, Sigma-Aldrich, St. Louis, MO, USA) and were blocked with bovine serum albumin (2%, Sigma-Aldrich). Using anti-CD74-monoclonal, anti-MIF-monoclonal, or anti-CD44-monoclonal antibodies, immunostaining was performed as described previously. [13, 14] 
Statistical analysis
All statistical determinations were carried out by the Statistical Package for the Social Sciences (IBM Statistics, USA). P < 0.05 was considered statistically significant. 
Results
Cell
Immunoblot analysis of CD74, MIF, and CD44
Western blot analysis was used to detect CD74, CD44, and MIF protein expression in MDA-MB-231, CAMA-1, and MDA-MB-435 cells By2 (anti-CD74), D-2 (anti-MIF), 156-3C11 (anti-CD44), and TU-02 (anti-α-tubulin) and Poly6221 (anti-β-actin). By2 (anti-CD74) is specific for CD74 isoforms 31-45 kDa and 156-3C11 (anti-CD44) is a mouse mAb that detects endogenous levels of total CD44 protein and is specific for most isoforms (80-90 kDa). The MIF-specific antibody, D-2, is a mouse monoclonal antibody mapping an epitope between amino acids 7- gel during performing of western immunoblotting, the band intensities of CD44, CD74, and MIF were measured by Image Studio Lite (LI-COR Biosciences Software) and were normalized with the band intensities of β-actin and were presented in Figure 3b .
Confocal microscopy
Laser scanning microscopy was performed to see the cell surface and intracellular expression of CD44, CD74, and MIF proteins using different wavelengths. The CAMA-1, MDA-MB-435, and MDA-MB-231 cell lines all exhibited expression of CD74, CD44, and MIF on the surface and intracellular membranes of cells [ Figure 4a and b]. CD74 or MIF was labeled with Alexa Fluor® 488 (green) and CD44 Alexa Fluor® 555 (red), and cell nuclei were stained with 4', 6-diamidino-2-phenylindole (blue).
Validation study of tumor antigens
To authenticate this study, the CD74, MIF, and CD44 expressions were determined in 226LDM cells, a normal immortalized breast luminal cells. Flow cytometric analysis was conducted to determine cell surface and intercellular expression of CD44, CD74, and MIF and the results are shown in Figure 5a . To further validate the role of CD74, MIF, and CD44 in these cancer cells, western immunoblotting was performed in which α-tubulin was used instead of β-actin as a loading control and the results of western immunoblotting are shown in Figure 5b . These results were further revalidated again by confocal laser scanning microscopy using an intracellular staining of CD74, MIF, and CD44 in 226LDM cells. The laser scanning showed no expression of CD74, but the expression of MIF and CD44 was noticed in these 226LDM cells [ Figure 5c ]. Flow cytometry data show that MIF was not detectable and CD44 was very weak on the cell surface but was higher intracellularly.
In the same manner, the expression of CD74, MIF, and CD44 on normal breast lysate and tissues (available commercially) was examined. The results revealed that CD74 was not expressed on normal breast lysate and tissues in contrast to MIF and CD44 [ Figure 6a and b]. Although normal breast lysate and tissues expressed MIF and CD44, the level was low compared to that in CAMA-1, MDA-MB-231, and MDA-MB-435 cells.
Discussion
To further understand the immunogenicity and tumorigenicity of breast cancer cells, the expression of HLA-A, B, and C and HLA-DR molecules in MDA-MB-231, CAMA-1, 226LDM, and MDA-MB-435 cells was investigated. HLA-A, B, and C expression was detected in MDA-MB231 and MDA-MB435 cells, but not in CAMA-1 and 226LDM cells. Conversely, HLA-DR was not detectable in any of the cell lines except MDA-MB-435 cells, which showed weak expression, as shown in Figure 1 . The expression of major histocompatibility (MHC) Class I and II in cancer cells, including lung, liver, melanoma, colon, and breast cancer, has been previously observed. [15] [16] [17] [18] Notably, Jabrane-Ferrat et al. [19, 20] reported that four of five different breast adenocarcinoma cell lines expressed cell-surface MHC Class I proteins. On the other hand, MHC Class I was either not expressed or downregulated in primary breast cancer tissue. [21] In this respect, it has been revealed that the expression of CD74, HLA-DR, and HLA-DM by tumor cells is a marker of better prognosis in breast cancer patients. Number of investigators noticed that HLA molecular expression improves cancer cells immunogenicity, and for this reason, they emphasized on antitumor T-cell response. [22] [23] [24] Thus, the expression of HLA-A, B, and C and HLA-DR molecules in breast cancer cell lines could be of considerable value for tumor immunity, potentially leading to efficient tumor antigen processing and presentation to T cells. [25] In the tumor immunotherapy design field, MHC Class II presentation has received much recent attention. [26, 27] Recently published data indicate that CD74, MIF, and CD44 have a role in the pathogenesis of solid tumors. [1, 7, 28] The data obtained have confirmed that cell surface and intracellular MIF, CD74, and CD44 molecules are obvious by flow cytometry and confocal microscopy. The western blotting results revealed that breast cancer cells express total protein of CD74, MIF, and CD44. Significantly, western blot analysis showed that the studied breast cancer cells express three different isoforms of CD74, the P33, P35, and P41 isoforms, which were detected at the expected molecular weights, the major form being the 33 kDa isoform [ Figure 6a] . [29] These findings differ from those obtained by Verjans et al. [30] who found that MDA-MB-231 and MDA-MB-468 cells express one CD74 isoform; however, it was not specified which isoform. Similarly, reports also showed that MDA-MB-435 also expresses P35 isoform of CD74. [31] Not only have these, THP-1 cells show expression of P33 and P43 isoforms of CD74. The cell surface and the total protein expression of CD74 were also studied in the MCF-7 cell line. [32] Data obtained from flow cytometry showed that MCF-7 cells express a moderate level of CD74 compared to the positive control Raji cell lines. Western blot results confirmed that MCF-7 cells express the total protein of CD74. However, MCF-7 cells expressed the P33 and P41 isoforms of CD74, in contrast to breast cancer cells. Theoretically, an additional 43 kDa form of CD74, the longest isoform, could be expected, but it has not yet been unequivocally detected in immunoprecipitates from human cells. Regulation of Class II MHC antigen presentation is regulated by the P33 and P35 isoforms while the T-cell selection in the thymus is monitored by P41 isoform. [29] CD74 aids in the export of MHC II/CD74 complexes from the endoplasmic reticulum as well as blocking untimely loading of peptides onto the MHC II molecules. [33] [34] [35] [36] [37] However, it has been newly suggested that elevated levels of CD74 expression may avert tumor antigen presentation by closing peptide cleft of MHC Class II molecule, thus preventing binding of antigenic peptides for T-cells presentation. [38, 39] In Humans, nearly 80% of the CD74 protein pool consists of the P33 isoform. However, P35 is considered the most enigmatic isoform. [36] Metodieva et al. [37] have suggested that P33 and P35, together, assist in antigen presentation; moreover, this process does not require the coexpression of further more CD74 isoform. [37, 38] Western blotting also demonstrated that CAMA-1 cells express two different isoforms of CD44; CD44 variant (CD44v) and CD44 standard (CD44s) [ Figure 6a ]. Few breast cancer cell lines, such as MDA-MB-468 and SUM149, express a number of isoforms of CD44s and CD44v. [40] It is likely that CD44 expression in breast cancer may be related with highly aggressive breast tumor subtypes or extremely invasive breast cancer cells. [41] To validate the present study, immortalized normal breast luminal cells (226LDM cells), breast (human) whole cell lysate obtained from adult normal tissue, and normal breast tissue slides were used as a model. The expression of CD74, MIF, and CD44 was investigated by flow cytometry, western blot, and microscopy. The findings confirmed that 226LDM cells did not express CD74 on the cell surface or intracellularly but express MIF and CD44, although in low levels compared to breast cancer cells. In the same manner, the results obtained from western blotting of normal breast lysate and histological immunostaining of breast tissue slides showed only positive detection of MIF and CD44 but not CD74. This result was expected because it has been established that the expression of CD74 is restricted to antigenpresenting cells including B cells, monocytes, macrophages, and dendritic cells (e.g., Langerhans cells).
[42]
Conclusion
The study shows evidence that breast cancer cells expressing three different isoforms of CD74. The CD74 plays a crucial role in breast cancer cells along with MIF and CD44. The results clearly indicate that CAMA-1, MDA-MB-231, and MDA-MB-435 cells are poorly immunogenic, expressing low levels of HLA-A, B, and C and HLA-DR. Longitudinal studies in breast cancer animal model and also in breast cancer patients are necessary to invent novel agents that can antagonize the effects of CD74, CD44, and MIF, thereby, we can better treat, prevent, or control the onset and/or progression of breast cancer. 
